RetinalGenix Technologies (RetinalGenix Technologies) EBITDA Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. RetinalGenix Technologies's EBITDA for the three months ended in Mar. 2024 was $-2.15 Mil. RetinalGenix Technologies's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, RetinalGenix Technologies's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

RetinalGenix Technologies EBITDA Margin % Historical Data

The historical data trend for RetinalGenix Technologies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RetinalGenix Technologies EBITDA Margin % Chart

RetinalGenix Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

RetinalGenix Technologies Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of RetinalGenix Technologies's EBITDA Margin %

For the Medical Devices subindustry, RetinalGenix Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RetinalGenix Technologies's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where RetinalGenix Technologies's EBITDA Margin % falls into.

RetinalGenix Technologies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

RetinalGenix Technologies's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.087	/	0
	=	%

RetinalGenix Technologies's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.145	/	0
	=	%

RetinalGenix Technologies (OTCPK:RTGN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

RetinalGenix Technologies EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954

Website

https://www.retinalgenix.com

RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.